0001144204-18-040076.txt : 20180726 0001144204-18-040076.hdr.sgml : 20180726 20180726135652 ACCESSION NUMBER: 0001144204-18-040076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180724 FILED AS OF DATE: 20180726 DATE AS OF CHANGE: 20180726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gaston-Dreyfus Remi CENTRAL INDEX KEY: 0001716639 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54717 FILM NUMBER: 18971227 MAIL ADDRESS: STREET 1: 46 RUE PIERRE CHARRON CITY: PARIS STATE: I0 ZIP: 75008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bionik Laboratories Corp. CENTRAL INDEX KEY: 0001508381 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 271340346 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 BUSINESS PHONE: 1.416.640.7887 MAIL ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 FORMER COMPANY: FORMER CONFORMED NAME: Drywave Technologies, Inc. DATE OF NAME CHANGE: 20130814 FORMER COMPANY: FORMER CONFORMED NAME: Strategic Dental Management Corp. DATE OF NAME CHANGE: 20101220 4 1 tv499376_4.xml OWNERSHIP DOCUMENT X0306 4 2018-07-24 0 0001508381 Bionik Laboratories Corp. BNKL 0001716639 Gaston-Dreyfus Remi C/O BIONIK LABORATORIES CORP. 483 BAY STREET, N105 TORONTO A6 M5G2C9 ONTARIO, CANADA 1 0 1 0 Common Stock 2018-07-24 4 C 0 43468547 0.0513 A 134672664 I Shares held through RGD Investissements and Lombard International Assurance SA Effective as of July 20, 2018, an aggregate amount of $2,006,943 in convertible promissory notes issued to RGD Investissements (the "Notes") converted in accordance with their terms into 43,468,547 shares of the Issuer's common stock. For purposes of the filing of this Form 4, the transaction date is deemed to be July 24, 2018, as that was the date that the Issuer preliminarily determined the number of shares of common stock that the Notes were convertible into in accordance with the terms of the Notes. The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction. /s/ Remi Gaston-Dreyfus 2018-07-25